6. Number of people experiencing adverse events/side effects.
| Study ID | Antibiotic class | Antibiotic | Antibiotic frequency and amount | Adverse event type | Number of participants with adverse events/side effects (n) | Total number of participants (N) | Duration of treatment |
| Shafuddin 2015 | Macrolide + tetracycline | Roxithromycin + doxycycline | Continuous (300 mg + 100 mg daily) |
All‐cause | 73 | 101 | 48 weeks follow‐up after 12 weeks active treatment (60 weeks) |
| Shafuddin 2015 | Macrolide | Roxithromycin | Continuous (100 mg daily) | All‐cause | 74 | 97 | 48 weeks follow‐up after 12 weeks active treatment (60 weeks) |
| Shafuddin 2015 | Macrolide + tetracycline | Roxithromycin + doxycycline | Continuous (300 mg + 100 mg daily) |
Treatment‐ related |
31 | 101 | 48 weeks follow‐up after 12 weeks active treatment (60 weeks) |
| Shafuddin 2015 | Macrolide | Roxithromycin | Continuous (100 mg daily) | Treatment‐ related |
33 | 97 | 48 weeks follow‐up after 12 weeks active treatment (60 weeks) |